Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Donald Berry

Physician Assistant Troy, MI Physician Assistant

NPI 1164870275 CMS profile 11098040

44201 Dequindre Rd, Beaumont Hospital - Troy, Troy, MI 48085

Open in the dashboard

General payments

$18,437

615 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Donald Berry of Troy, MI is reported in the CMS Open Payments database as having received $18,437 across 615 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,802 112
2024 General $5,003 116
2023 General $2,926 129
2022 General $2,886 120
2021 General $4,821 138

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Donald Berry
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Donald Berry were reported at $2,802. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Donald Berry Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $4,821 $132 $37–$438 $132
2022 $2,886 $155 $48–$522 $149
2023 $2,926 $167 $52–$557 $160
2024 $5,003 $178 $55–$600 $164
2025 $2,802 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Teleflex LLC $3,865 34 payments
  2. Axonics Modulation Technologies, Inc. $2,108 48 payments
  3. Coloplast Corp $1,275 11 payments
  4. Sumitomo Pharma America, Inc. $1,153 54 payments
  5. Astellas Pharma US Inc $1,092 54 payments
  6. Janssen Biotech, Inc. $867 45 payments
  7. Pfizer Inc. $668 36 payments
  8. Antares Pharma, Inc. $621 32 payments
  9. Dendreon Pharmaceuticals LLC $569 21 payments
  10. AbbVie, Inc. $479 26 payments
  11. Other $5,741 254 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $13,662 598 payments
  2. Travel and Lodging $4,203 11 payments
  3. Education $573 6 payments
Products named General payments · program years 2021–2025
  1. UROLIFT $1,970 16 payments
  2. UroLift System $1,649 12 payments
  3. Axonics $1,207 34 payments
  4. Titan $1,192 6 payments
  5. XTANDI $1,154 61 payments
  6. Axonics r-SNM System $1,050 17 payments
  7. Bulkamid $896 14 payments
  8. ORGOVYX $865 38 payments
  9. ERLEADA $701 38 payments
  10. PROVENGE $569 21 payments
  11. Other $9,003 456 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

1,299

Median for Physician Assistant: 241

Drug cost

$387,050

Median for Physician Assistant: $4,110

Branded share of claims

57.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 248 $190,346
Gemtesa Vibegron Brand 144 $127,277
Mirabegron Er Mirabegron Brand 57 $47,756
Tolterodine Tartrate Er Tolterodine Tartrate Brand 67 $5,526
Tamsulosin Hcl Generic 177 $3,454
Potassium Citrate Er Potassium Citrate Brand 13 $2,887
Methenamine Hippurate Generic 40 $2,603
Finasteride Generic 71 $1,250
Oxybutynin Chloride Er Oxybutynin Chloride Brand 51 $1,239
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 74 $1,088

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ORGOVYX
  • Sumitomo Pharma America, Inc. $309
  • PFIZER INC. $27
$336 — —
PROVENGE
  • Dendreon Pharmaceuticals LLC $137
$137 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $133
$133 144 —
XTANDI
  • Astellas Pharma US Inc $99
  • PFIZER INC. $27
$126 — —
LYNPARZA
  • Merck Sharp & Dohme Corporation $83
$83 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

615 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record